Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for XNCR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2012. Start Trial.
Date Value
June 30, 2026 -55.66M
March 31, 2026 -67.63M
December 31, 2025 -51.71M
September 30, 2025 -30.82M
June 30, 2025 -36.37M
March 31, 2025 -16.22M
December 31, 2024 -49.84M
September 30, 2024 -26.02M
June 30, 2024 -65.34M
March 31, 2024 -55.26M
December 31, 2023 181.21M
September 30, 2023 -27.28M
June 30, 2023 -38.20M
March 31, 2023 -30.61M
December 31, 2022 -24.43M
September 30, 2022 -1.168M
June 30, 2022 44.27M
March 31, 2022 5.815M
December 31, 2021 61.79M
September 30, 2021 -39.02M
June 30, 2021 -9.654M
March 31, 2021 -29.97M
December 31, 2020 17.08M
September 30, 2020 -3.866M
June 30, 2020 -27.68M
Date Value
March 31, 2020 9.46M
December 31, 2019 -19.58M
September 30, 2019 -6.477M
June 30, 2019 109.16M
March 31, 2019 -18.73M
December 31, 2018 -16.78M
September 30, 2018 -10.31M
June 30, 2018 -28.42M
March 31, 2018 -24.24M
December 31, 2017 -6.666M
September 30, 2017 -3.509M
June 30, 2017 -12.88M
March 31, 2017 -10.55M
December 31, 2016 -15.79M
September 30, 2016 134.07M
June 30, 2016 -9.369M
March 31, 2016 -14.30M
December 31, 2015 -3.845M
September 30, 2015 39.52M
June 30, 2015 -6.916M
March 31, 2015 -2.093M
December 31, 2014 -5.864M
September 30, 2014 -4.72M
June 30, 2014 -5.774M
March 31, 2014 -4.993M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
UroGen Pharma Ltd. -35.02M
MeiraGTx Holdings Plc -38.54M
Regeneron Pharmaceuticals, Inc. 813.00M
Ironwood Pharmaceuticals, Inc. 58.28M
MacroGenics, Inc. -40.75M